Delivery of anti-migraine compounds through an inhalation route
First Claim
1. A method of treating migraine comprising administering a therapeutic amount of a lidocaine, verapamil, diltiazem, isometheptene, or lisuride condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% lidocaine, verapamil, diltiazem, isometheptene, or lisuride degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates to the delivery of anti-migraine compounds through an inhalation route. Specifically, it relates to aerosols containing lidocaine, verapamil, diltiazem, isometheptene, or lisuride that are used in inhalation therapy. In a method aspect of the present invention, lidocaine, verapamil, diltiazem, isometheptene, or lisuride is administered to a patient through an inhalation route. The method comprises: a) heating a composition of lidocaine, verapamil, diltiazem, isometheptene, or lisuride, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles with less than 5% drug degradation products. In a kit aspect of the present invention, a kit for delivering lidocaine, verapamil, diltiazem, isometheptene, or lisuride through an inhalation route is provided which comprises: a) a thin coating of a lidocaine, verapamil, diltiazem, isometheptene, or lisuride composition and b) a device for dispensing said thin coating as a condensation aerosol.
-
Citations
20 Claims
-
1. A method of treating migraine comprising administering a therapeutic amount of a lidocaine, verapamil, diltiazem, isometheptene, or lisuride condensation aerosol, having an MMAD less than 3 μ
- m and less than 5% lidocaine, verapamil, diltiazem, isometheptene, or lisuride degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
-
11. A method of administering lidocaine, verapamil, diltiazem, isometheptene, or lisuride to a patient to achieve a peak plasma drug concentration rapidly, comprising administering to the patient by inhalation an aerosol of lidocaine, verapamil, diltiazem, isometheptene, or lisuride having less than 5% lidocaine, verapamil, diltiazem, isometheptene, or lisuride degradation products and an MMAD less than 3 microns wherein the peak plasma drug concentration of lidocaine, verapamil, diltiazem, isometheptene, or lisuride is achieved in less than 0.1 hours.
-
12. A kit for delivering a drug aerosol comprising:
-
a) a thin coating of a lidocaine, verapamil, diltiazem, isometheptene, or lisuride composition, and b) a device for dispensing said thin coating as a condensation aerosol. - View Dependent Claims (13, 14, 15, 16, 17, 18, 19, 20)
-
Specification